Kozikowski A P, Araldi G L, Boja J, Meil W M, Johnson K M, Flippen-Anderson J L, George C, Saiah E
Drug Discovery Program, Institute of Cognitive and Computational Sciences, Georgetown University Medical Center, 3970 Reservoir Road, NW, Washington, D.C. 20007-2197, USA.
J Med Chem. 1998 May 21;41(11):1962-9. doi: 10.1021/jm980028+.
To discover agents that might be useful in the treatment of cocaine abuse, we have chosen to re-explore a class of molecules that was first reported by Clarke et al. in 1973 and that was and shown to lack locomotor stimulatory activity in mice. These compounds are piperidine-3-carboxylic acid esters bearing a 4-chlorophenyl group in position 4, and as such, these structures may be viewed as truncated versions of the WIN series compounds, i.e., they lack the two-carbon bridge of the tropanes. All members of this class were synthesized starting from arecoline hydrobromide and obtained in optically pure form through resolution methods using either (+)- or (-)-dibenzoyltartaric acid. Interestingly, we have found that these piperidines do, in fact, exhibit substantial affinity in both WIN 35, 428 binding at the dopamine transporter and in the inhibition of [3H]dopamine uptake. Of all of the compounds synthesized, the 3-n-propyl derivative (-)-9 was found to be the most potent with a binding affinity of 3 nM. This simple piperidine is thus 33-fold more potent than cocaine in binding affinity and 29-fold more potent in its inhibition of dopamine uptake. Although no efforts have presently been made to "optimize" binding affinity at the DAT, the substantive activity found for the n-propyl derivative (-)-9 is remarkable; the compound is only about 10-fold less active than the best of the high-affinity tropanes of the WIN series. As a further point of interest, it was found that the cis-disubstituted piperidine (-)-3 is only about 2-fold more potent than its trans isomer (+)-11. This result stands in sharp contrast to the data reported for the tropane series, for the epimerization of the substituent at C-2 from beta to alpha has been reported to result in a lowering of activity by 30-200-fold. This smaller spread in binding affinities for the piperidines may reflect the smaller size of these molecules relative to the tropanes, which allows both the cis and the trans isomers to adjust themselves to the binding site on the DAT. Our present demonstration that these piperidine structures do, in fact, possess significant DAT activity, taken together with their reported lack of locomotor activity, provides a compelling argument for exploring this class of molecules further in animal behavioral experiments. The present work thus broadens the scope of structures that may be considered as lead structures in the search for cocaine abuse medications.
为了发现可能对治疗可卡因滥用有用的药物,我们选择重新研究一类分子,这类分子最早由克拉克等人于1973年报道,并且已证明在小鼠中缺乏运动刺激活性。这些化合物是在4位带有4-氯苯基的哌啶-3-羧酸酯,因此,这些结构可被视为WIN系列化合物的截短版本,即它们缺少托烷的二碳桥。这一类的所有成员均从氢溴酸槟榔碱开始合成,并通过使用(+)-或(-)-二苯甲酰酒石酸的拆分方法以光学纯形式获得。有趣的是,我们发现这些哌啶实际上在多巴胺转运体上的WIN 35,428结合以及对[3H]多巴胺摄取的抑制方面均表现出显著的亲和力。在所有合成的化合物中,3-正丙基衍生物(-)-9被发现是最有效的,结合亲和力为3 nM。因此,这种简单的哌啶在结合亲和力方面比可卡因强33倍,在抑制多巴胺摄取方面强29倍。尽管目前尚未努力“优化”在多巴胺转运体上的结合亲和力,但正丙基衍生物(-)-9所具有的实质性活性是显著的;该化合物的活性仅比WIN系列中亲和力最高的托烷类化合物中最好的低约10倍。另一个有趣的点是,发现顺式二取代哌啶(-)-3的活性仅比其反式异构体(+)-11高约2倍。这一结果与托烷系列报道的数据形成鲜明对比,据报道,C-2位取代基从β-向α-的差向异构化会导致活性降低30至200倍。哌啶类化合物在结合亲和力上的这种较小差异可能反映了这些分子相对于托烷类化合物较小的尺寸,这使得顺式和反式异构体都能调整自身以适应多巴胺转运体上的结合位点。我们目前的证明表明这些哌啶结构实际上具有显著的多巴胺转运体活性,再加上它们报道的缺乏运动活性,为在动物行为实验中进一步探索这类分子提供了令人信服的论据。因此,目前的工作拓宽了在寻找可卡因滥用药物时可被视为先导结构的结构范围。